Rihab Bouchareb

Dr. Rihab Bouchareb

Translational Research, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Pharmacological Research
Verified
Journal Article
Closed access
RSRajvir Singh
Rajvir Singh
RKRavinder K. Kaundal
Ravinder K. Kaundal
BZBaoyin Zhao
Baoyin Zhao
Rihab BoucharebRihab Bouchareb
Rihab Bouchareb
Djamel LebecheDjamel Lebeche
Djamel Lebeche

1 January 2021 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
Rihab BoucharebRihab Bouchareb
Rihab Bouchareb
SGSandra Guauque-Olarte
Sandra Guauque-Olarte
JSJustin Snider
Justin Snider
DZDevyn Zaminski
Devyn Zaminski
AAAnelechi Anyanwu
Anelechi Anyanwu
DLDjamel Lebeche
Djamel Lebeche
• ECM proteins play an important role in maintaining the structural architecture and the mechanical behavior of the aortic valve. • Network analysis highlights a strong connection between metabolic markers and ECM proteins. • MXRA5 and FNDC1 were identified as new biomarkers of aortic stenosis in 2 independent cohorts

Verified
Journal Article
Open access
PDF file
MNMohamed J. Nsaibia
Mohamed J. Nsaibia
ADAnichavezhi Devendran
Anichavezhi Devendran
EGEshak Goubaa
Eshak Goubaa
Jamal BouitbirJamal Bouitbir
Jamal Bouitbir
RORomain Capoulade Inserm DR Grand Ouest
Romain Capoulade Inserm DR Grand Ouest
Rihab BoucharebRihab Bouchareb
Rihab Bouchareb
Calcific Aortic Valve Disease (CAVD) is a fibrocalcific disease. Lipoproteins and oxidized phospholipids play a substantial role in CAVD; the level of Lp(a) has been shown to accelerate the progression of valve calcification. Indeed, oxidized phospholipids carried by Lp(a) into the aortic valve stimulate endothelial dysfunction and promote inflammation. Inflammation and growth factors actively promote the synthesis of the extracellular matrix (ECM) and trigger an osteogenic program. The accumulation of ECM proteins promotes lipid adhesion to valve tissue, which could initiate the osteogenic program in interstitial valve cells. Statin treatment has been shown to have the ability to diminish the death rate in subjects with atherosclerotic impediments by decreasing the serum LDL cholesterol levels. However, the use of HMG-CoA inhibitors (statins) as cholesterol-lowering therapy did not significantly reduce the progression or the severity of aortic valve calcification. However, new clinical trials targeting Lp(a) or PCSK9 are showing promising results in reducing the severity of aortic stenosis. In this review, we discuss the implication of lipids in aortic valve calcification and the current findings on the effect of lipid-lowering therapy in aortic stenosis.

17 November 2021 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
SSStephanie L. Sellers
Stephanie L. Sellers
GGGaurav S. Gulsin
Gaurav S. Gulsin
DZDevyn Zaminski
Devyn Zaminski
RBRong Bing
Rong Bing
ALAzeem Latib
Azeem Latib
Rihab BoucharebRihab Bouchareb
Rihab Bouchareb
• Activated platelets are associated with AS. • Platelets are a player in bioprosthetic valve dysfunction. • Randomized trials have assessed clinical outcomes with various antiplatelet/anticoagulation strategies in patients undergoing TAVR.

8 March 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
MMMaiko Matsui
Maiko Matsui
Rihab BoucharebRihab Bouchareb
Rihab Bouchareb
MSMara Storto
Mara Storto
YHYasin Hussain
Yasin Hussain
AGAndrew Gregg
Andrew Gregg
GPGeoffrey S. Pitt
Geoffrey S. Pitt
Calcific aortic valve disease (CAVD) is heritable, as revealed by recent GWAS. While polymorphisms linked to increased expression of CACNA1C — encoding the Ca V 1.2 L-type voltage-gated Ca 2+ channel — and increased Ca 2+ signaling are associated with CAVD, whether increased Ca 2+ influx through the druggable Ca V 1.2 causes CAVD is unknown. We confirmed the association between increased Ca V 1.2 expression and CAVD in surgically removed aortic valves from patients. We extended our studies with a transgenic mouse model that mimics increased Ca V 1.2 expression within aortic valve interstitial cells (VICs). In young mice maintained on normal chow, we observed dystrophic valve lesions that mimic changes found in presymptomatic CAVD and showed activation of chondrogenic and osteogenic transcriptional regulators within these valve lesions. Chronic administration of verapamil, a Ca V 1.2 antagonist used clinically, slowed the progression of lesion development in vivo. Exploiting VIC cultures, we demonstrated that increased Ca 2+ influx through Ca V 1.2 drives signaling programs that lead to myofibroblast activation of VICs and upregulation of genes associated with aortic valve calcification. Our data support a causal role for Ca 2+ influx through Ca V 1.2 in CAVD and suggest that early treatment with Ca 2+ channel blockers is an effective therapeutic strategy.

24 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ADAbdellaziz Dahou
Abdellaziz Dahou
FVFNU Vikky
FNU Vikky
MBMERIEM BKHACHE
MERIEM BKHACHE
MDMerouane Djellal
Merouane Djellal
Xiaofeng YangXiaofeng Yang
Xiaofeng Yang
Rihab BoucharebRihab Bouchareb
Rihab Bouchareb
Aortic stenosis (AS) is the most common valvular heart disease in developed countries, and its prevalence is higher in older patients. Clinical studies have shown gender disparity in the pathogenesis and the progression of aortic stenosis. This disparity has led to several overwhelming questions regarding its impact on the clinical outcomes and treatment of the disease and the requirement of personalized sex-specific approaches for its management. Indeed, aortic stenosis differs in the pathophysiological response to pressure overload created by the stenosis in women compared to men, which would translate into differences in cardiac remodeling and clinical outcomes. Several studies have focused on understanding the differences regarding disease progression according to biological gender and have found that sex hormones play a crucial role. Sex hormones affect many metabolic processes, thus activating crucial cell signaling and energy metabolism through mitochondrial activity. Yet, there is still a significant gap in knowledge on how biological sex influences the pathophysiology of AS. In this review, we have discussed studies that point to the role of sex-related physiological differences in the molecular pathways and the clinical presentation of the disease and outcome in women and men. We used the format of narrative review to review and summarize the body of literature without being systematic but with taking great care of considering the most impactful data available to date on the topic, especially randomized trials, metanalyses, and prospective studies and registries when available, as well as experimental studies with rigorous methodological approaches regarding the basic mechanisms and pathophysiology of the disease in women compared to men. The opinion of the authors on a particular issue or finding was expressed when appropriate for clarification.